ASLN Aslan Pharmaceuticals
- 0.4153
- -0.0327-7.30%
- 0.4250
- +0.0097+2.34%
Aslan Pharmaceuticals News
12 Health Care Stocks Moving In Friday's After-Market Session
GainersBluejay Diagnostics (NASDAQ:BJDX) shares increased by 11.0% to $0.73 during Friday's after-market session. The company's market cap stands at $1.9 million. China Pharma Holdings, Inc. Common St
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.5%
Asian equities traded in the US as American depositary receipts were trending higher Friday morning, rising 0.6% to 1,850.73 on the S&P Asia 50 ADR Index, which is poised to end the week around 3.5% h
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading
Tech stocks were leading Asian equities traded in the US as American depositary receipts lower Thursday morning, falling 0.83% to 1,827.37 on the S&P Asia 50 ADR Index. From North Asia, the gainers we
Express News | ASLAN Pharmaceuticals Disclosed Late Breaking Abstract On Eblasakimab In COPD Accepted For Presentation At The American Thoracic Society International Conference
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
SAN MATEO, Calif. and SINGAPORE, April 24, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Astria Therapeutics (ATXS) and Aslan Pharmaceuticals (ASLN)
Asian Equities Traded in the US as American Depositary Receipts Open Week Higher
Asian equities traded in the US as American depositary receipts kicked off the week on a positive note, rising 0.88% to 1,799.39 on the S&P Asia 50 ADR Index in Monday trading. From North Asia, the ga
Aslan Pharmaceuticals' Eblasakimab Shows Promise
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
Interim readout of 22 patients shows unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab-experienced AD patients treated with 400mg eblasakimab weekly achieved EASI-90 (at least a 90% reduction in their Eczema Area Severity Index (EASI) score) and 66.7% achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks, versus 14.3% of patients on placebo.
Express News | Aslan Pharmaceuticals Reports Interim Results From Phase 2 Study Of Eblasakimab In Dupilumab-Experienced Atopic Dermatitis Patients
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
ASLAN Pharmaceuticals (Nasdaq: ASLN) today announced that it received a letter (the "Letter") on April 18, 2024 from The Nasdaq Stock Market ("Nasdaq") informing the Company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company's stockholders' equity be at least $2.5 million (the "Stockholders' Equity Requirement").
Asian Equities Traded in the US as American Depositary Receipts Fall Again in Friday Trading
Asian equities traded in the US as American depositary receipts were trending lower Friday morning, declining 0.69% to 1,786.62 on the S&P Asia 50 ADR Index. The index is poised to close out the week
Asian Equities Traded in the US as American Depositary Receipts Remain Flat in Wednesday Trading
After opening the trading session in positive territory, Asian equities traded in the US as American depositary receipts fell flat Wednesday morning, declining 0.061% to 1,823.73 on the S&P Asia 50 AD
Financial, Telecoms Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday
Financial and telecoms stocks led Asian equities traded in the US as American depositary receipts sharply lower Tuesday morning, falling 1.33% to 1,822.99 on the S&P Asia 50 ADR Index. From North Asia
Express News | HC Wainwright & Co. Reiterates Buy on ASLAN Pharma, Maintains $9 Price Target
ASLAN Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/15/2024 1646.89% HC Wainwright & Co. → $9 Reiterates Buy → Buy 03/18/2024 1646.89% HC Wainwright & Co.
Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Rewalk Robotics (LFWD) and Apellis Pharmaceuticals (APLS)
Asian Equities Traded in the US as American Depositary Receipts Fall in Friday Trading
Asian equities traded in the US as American depositary receipts were sharply lower, falling 1.89% to 1,877.95 Friday morning on the S&P Asia 50 ADR Index. From North Asia, the gainers were led by fint
Aslan Pharmaceuticals Launches $12M ADS Offering
ASLAN Pharmaceuticals GAAP EPADS of -$0.78
Analysis
Price Target
No Data
